Table 2

Comparison of the change in BMI and lung function the year before and after 1 year of study participation

CFRD FH−
IGT
InsulinRepaglinidePlaceboInsulinRepaglinidePlacebo
n6120
BMI
    −12 months to baseline (kg/m2)−0.30 ± 0.21−0.14 ± 0.21−0.29 ± 0.25−0.60 ± 0.30−0.08 ± 0.40−0.66 ± 0.27
    Baseline to +12 months (kg/m2)0.39 ± 0.210.15 ± 0.21−0.02 ± 0.25−0.26 ± 0.30−0.71 ± 0.400.24 ± 0.27
    P value0.020.330.450.430.280.02
FVC
    −12 months to baseline (% predicted)−5.8 ± 2.0−5.5 ± 2.1−4.3 ± 2.52.0 ± 4.2−3.4 ± 5.6−2.8 ± 3.7
    Baseline to +12 months−0.5 ± 2.0−2.1 ± 2.1−1.1 ± 2.5−10.3 ± 4.2−3.1 ± 5.6−5.1 ± 3.7
    P value0.210.250.370.050.960.6
FEV1
    −12 months to baseline (% predicted)−5.7 ± 2.2−6.5 ± 2.2−0.5 ± 2.70.6 ± 5.6−2.5 ± 7.42.8 ± 4.9
    Baseline to +12 months−1.8 ± 2.2−1.3 ± 2.2−3.0 ± 2.712.1 ± 5.6−4.9 ± 7.4−11.5 ± 4.9
    P value0.210.100.510.120.820.05
  • Data are means ± SEM.